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Premature subclinical atherosclerosis in
children and young adults with juvenile
idiopathic arthritis. A review considering
preventive measures
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Abstract
Many studies show that Juvenile Idiopathic Arthritis (JIA) is associated with early subclinical signs of atherosclerosis.
Chronic inflammation per se may be an important driver but other known risk factors, such as dyslipidemia,
hypertension, insulin insensitivity, a physically inactive lifestyle, obesity, and tobacco smoking may also contribute
substantially. We performed a systematic review of studies through the last 20 years on early signs of subclinical
atherosclerosis in children and adolescents with JIA with the purpose of investigating whether possible risk factors,
other than inflammation, were considered.
We found 13 descriptive cross sectional studies with healthy controls, one intervention study and two studies on
adults diagnosed with JIA. Only one study addressed obesity, and physical activity (PA) has only been assessed in
one study on adults with JIA and only by self-reporting. This is important as studies on PA in children with JIA have
shown that most patients are less physically active than their healthy peers, and as physical inactivity in several large
studies of normal schoolchildren is found to be associated with increased clustering of risk factors for cardiovascular
disease. It is thus possible that an inactive lifestyle in patients with JIA is an important contributor to development of
the subclinical signs of atherosclerosis seen in children with JIA, and that promotion of an active lifestyle in childhood
and adolescence may diminish the risk for premature atherosclerotic events in adulthood.
Keywords: Juvenile idiopathic arthritis, Chronic arthritis, Premature atherosclerosis, Adipositas, BMI, Physical activity,
Tobacco smoking, Prevention of atherosclerosis
Background
Juvenile Idiopathic Arthritis (JIA) is the collective term
for a clinically diverse group of rheumatic inflammatory
syndromes of unknown etiology, which may present as a
systemic inflammation, an isolated arthritis or in associ-
ation with other organ specific inflammatory disorders
such as psoriasis and uveitis. The annual incidence in
the Western world is 16–150 per 100.000 children, mak-
ing it the most common chronic inflammatory disease
in childhood [1]. Several phenotypes are recognized, ran-
ging from self-limiting forms involving a few joints, to
erosive polyarthritis and systemic JIA (sJIA), all of a
relapsing and remitting nature. Although some patients
enter spontaneous permanent remission, 41–78 % of pa-
tients require continuous or recurrent treatment in
adulthood [1–4]. JIA is thus a long lasting chronic in-
flammatory disease, and concern has been raised, as in
rheumatoid arthritis (RA), regarding the risk of prema-
ture development of cardiovascular disease. Indeed, sev-
eral studies of children with JIA have described the
occurrence of early subclinical signs of atherosclerosis.
Family disposition for cardiovascular disease, dyslipid-
emia, hypertension, and diabetes, as well as lifestyle fac-
tors such as obesity, physical inactivity, and tobacco
smoking are known individually significant risk factors
for accelerated development of atherosclerosis; cohort
studies of the general population such as Framingham
Heart Study [5] and Young Finns [6, 7] have helped in
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identifying these factors. More recently the concept has
emerged that chronic systemic inflammation may also
contribute. This is based primarily on large cohort stud-
ies of patients with RA. For example, a meta-analysis of
mainly community based cohorts and case–control stud-
ies of incident cardiovascular events including myocar-
dial infarction, cerebrovascular accidents and congestive
heart failure in 41,490 patients with RA indicates an in-
crease in risk of about fifty percent compared with the
general population [8]. Likewise treating to the lowest
possible levels of disease activity has been shown to re-
duce the risk for cardiovascular events in patients with
RA [9].
However, focusing too narrowly on persistent inflam-
mation as a driver for the development of atherosclerosis
risks overlooking equally important, and potentially re-
versible, risk factors; this is well-illustrated in a recent
report on progression of atherosclerosis in patients with
RA by del Rincón et al. [10]. For this reason we reviewed
existing studies reporting early or subclinical signs of
cardiovascular disease in children with JIA to see
whether known risk factors were taken into account.
Studies published in English were searched through
PubMed (National Library of Medicine), primarily mak-
ing use of MeSH terms and free text and secondarily by
following key references in relevant articles. Studies from
the last 20 years are included, as this covers a period of
more efficacious treatment for JIA.
Risk for development of premature atherosclerosis in
childhood and adolescence
Acquired overt cardiovascular disease is rare during
childhood. However, post mortem studies of the vascula-
ture of apparently healthy children and young adults, 2
to 39 years of age, have shown that microscopic lipid de-
posits and inflammatory reactions, the hallmark of ath-
erosclerosis, are found in the arterial intima of infants
and young children and that fatty streaks and fibrous
plaques are seen in the aorta and coronary arteries of
most teen-agers [11–14], suggestive of atherosclerosis as
a continuing process beginning early in life. The natural
history of the arterial lesions was investigated through
studies at the same location in the arterial tree across
different age groups. Progression to more severe athero-
sclerosis was associated with raised levels of the non-
High-Density-Lipoprotein fraction of cholesterol (non-
cHDL) in blood, hypertension, impaired glucose toler-
ance, obesity, and tobacco smoking, with each factor
reinforcing the others [15].
In addition there is mounting evidence for the import-
ance of physical activity (PA) for continuing cardiovascu-
lar health through childhood, adolescence and
adulthood [16–21]. Indeed, being physically active is one
of the seven ideal metrics for continuing cardiovascular
health issued by the American Heart Association [22],
the other six metrics being non-smoking, keeping a
healthy diet, maintaining normal blood pressure, normal
glucose- and lipid-metabolism, and normal weight.
Large longitudinal observational population-based
studies beginning in childhood or adolescence confirm
the association with structural or functional vascular
changes in adulthood, indicative of future clinically im-
portant cardiovascular disease [6, 23–28] (Table 1).
Surrogate markers of preclinical atherosclerosis
In adults, several non-invasive techniques for evaluation
of endothelial function and structural changes in the ar-
terial wall have proven reliable markers for later devel-
opment of acute cardiovascular events and are now
included in many clinical studies as surrogate markers of
atherosclerosis.
In a Scientific Statement from the American Heart As-
sociation, Urbina et al. review assessment of subclinical
atherosclerosis in children and adolescents by these
techniques [29].
A short description of the non-invasive methods used
in investigations of cardiovascular function in JIA is
given in Table 2, together with relevant references.
As well-defined atherosclerotic events like myocardial
infarcts and stroke are very rare in childhood, the prog-
nostic value of the described abnormalities must await
clinical studies reaching into mid-late adulthood. Never-
theless the association established between the structural
and functional surrogate markers of early atherosclerosis
and the above-mentioned known risk factors for devel-
opment of clinical overt atherosclerosis [6] make these
simple and non-invasive techniques attractive as tools in
studies of cardiovascular health in children with JIA.
At present, there are no available prognostic bio-
markers in the blood with acceptable sensitivity and spe-
cificity for subclinical cardiovascular disease [30, 31].
Investigations of cardiovascular structure and function in
children and adolescents with JIA
Although severe extra-articular complications may occur
in the acute phase of systemic JIA (sJIA), including
Table 1 Known risk factors in childhood and adolescence for
premature development of cardiovascular disease
Family disposition
Hypertension
Hypercholesterolemia, dyslipidemia
Insulin resistance
Obesity
Physical inactivity
Smoking
References given in the text
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serositis, myocarditis, renal amyloidosis, and cerebral
vasculitis, there is no evidence of cardiac and cardiovas-
cular involvement as common clinical features in the
chronic phase of JIA during childhood and adolescence.
However, JIA is a chronic inflammatory disease, and
concern regarding premature development of cardiovas-
cular disease, as seen in patients with RA, has led to per-
formance of echocardiographic and tonometric studies,
as well as studies on endothelial function in children
and young adults with JIA with no clinical signs of car-
diovascular dysfunction and with no family disposition
for cardiovascular disease (Table 3).
In the available cross-sectional studies measuring
signs of early atherosclerosis in JIA, life style risk fac-
tors for development of premature atherosclerosis
were not, in general, considered systematically. Lipids
were measured in several studies and showed no con-
sistent pattern, but only one study specifically ad-
dressed overweight status [32]. None of the studies
took PA into consideration.
There is, at present, only one intervention study [33, 34]
that has examined the effect of anti-inflammatory treat-
ment on cIMT. In a group of prepubertal patients with
oligo- and polyarticular JIA, with a control group only at
baseline, cIMT was found to be significantly increased in
JIA patients at enrolment, with a significant decrease doc-
umented after 1 year of anti-inflammatory medication,
(NSAID, MTX, Etanercept). Treatment was also corre-
lated with a significant reduction in diastolic and systolic
blood pressure and an improvement in inflammatory
markers and lipids. Lifestyle was not documented, how-
ever, leaving open the possibility that the cardiovascular
improvement was due to a healthier, more active lifestyle
which might have occurred in parallel with decreasing dis-
ease activity.
Prospective long-term studies of JIA have focused on
the prevalence and severity of arthritis and the impact
on musculoskeletal function; only few studies report
data on cardiovascular health in adults with a history of
JIA [35–37]. Raab et al. [36] collected information from
adult patients with JIA treated with biologics. Cardiovas-
cular disease, mainly arterial hypertension, was reported
in a total of 9.9 %, a proportion similar to that seen in
an age and gender matched control group drawn from
a community sample. However, a disproportionally
high rate was noted in patients with a history of sJIA,
where 6 out of 15 patients reported hypertension; 2/3
of the patients with sJIA received treatment with
corticosteroids.
Aulie et al. [37] examined arterial stiffness by use of
PWV and AIx in a 29-year follow up study of young
adults diagnosed with JIA and still having active dis-
ease. These authors found a small, but significant, in-
crease in arterial stiffness by PWV associated with
elevated diastolic blood pressure. AIx was not signifi-
cantly different from controls but was negatively cor-
related with markers of active disease, use of
prednisolone, self-reported lower PA, and daily smok-
ing. Coronary artery calcification was also not more
frequent in young adults with JIA than in the general
population, but was positively correlated with waist
circumference, BMI, systolic blood pressure, blood
glucose and daily prednisolone. Insulin resistance was
increased in the patients as was, unexpectedly, the
frequency of daily smoking. The study by Aulie et al.
[37] is the only report in which all known risk factors
for atherosclerosis were taken into consideration
along with disease characteristics. Assessment of PA,
however, was only documented by self-report and not
objectively measured.
Table 2 Non-invasive methods for investigation of cardiovascular function
Measurement Abbreviation Principle References
Coronary artery calcification CAC Arterial wall structure, atherosclerotic plaques [7, 29, 37]
Intimal and Medial thickness of the wall in
carotis or aorta
cIMT (carotis) , aIMT
(aorta)
Arterial wall structure [21, 26, 29,
71]
Left ventricle mass index LVMi Left ventricular dimensions adjusted for height, weight, age, and
sex
[32]
Pulse wave velocity PWV Direct measure of stiffness in large arteries [29, 37, 72,
73]
Augmentation index AIx Indirect measure of arterial stiffness combining arterial and
ventricular function
[29, 37, 73]
Flow mediated dilation FMD Endothelial cell function [29, 71,
74–76]
Glyceryl trinitrate mediated flow GTN-mediated dilation Arterial wall function [71]
Arterial distensibility Direct measure of stiffness in large arteries [29, 71]
Plasma natriuretic peptide NT-pro-BNP Ventricular dysfunction [77]
Troponin T TnT Myocardial damage [77]
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Table 3 Investigations of structure and function of heart and / or arteries in children and adolescents with JIA with no clinical signs of cardiovascular dysfunction
Ref. Design No. of patients
and controls
Age-group Numbers of patients
and subtypes
Number of patients in
treatment at time of
investigation
Study parameters Significant findings
Stamato et al.
1995 [78]
Descriptive cross-sectional 36 10–17.5 36 HLA-B27 pos. with
spondylarthropathy
No information Echocardiographic assessment
of left ventricle and the
outflow tract.
Mild aortal regurgitation in patients
unrelated to disease duration
with an age matched
healthy control group
33 * 6-18 * Atrio-ventricular conduction
Disease duration
Huppertz et al.
2000 [79]
Descriptive cross- sectional 40 6–26 35 HLA-B27 pos ERA No information Echocardiographic
assessment of the left
ventricle functions
before and after exercise.
HLA-B27 positive ERA possibly at risk
for development of aortic regurgitation
and impaired myocardial relaxation
with a control group of age
and sexmatched HLA-B27
neg JIA and 25 healthy
children
15 + 25 * 6 - 25 * 3 oligo Atrio-ventricular conduction
1 sJIA BP
1 unclassified
Oguz et al.
2000 [80]
Descriptive cross- sectional. 30 3–15 19 oligo Mainly NSAID Echocardiographic
assessment of the left
ventricle function
Higher systolic and diastolic BP, but
within normal limits, and diastolic
dysfunction of abnormal relaxation
type in patients
with an age matched
healthy control group
30 * 10 poly The patient with systemic
JIA received corticosteroid
BP
1 sJIA. One unspecified patient
received MTX
Argyropoulou
et al. 2003 [81]
Descriptive cross-sectional 31 No data 18 oligo No information Evaluation by MR of aortic
distensibility and PWV
Lower distensibility and higher PWV in
patients unrelated to JIA subtype
with an age matched
healthy control group
28 * 6 poly Disease activity No correlations between aortic
distensibility / PWV and metabolic and
disease activity parametersInsulin sensitivity
Lipid profile7 sJIA
Bharti et al.
2004 [82]
Descriptive cross-sectional. 35 No data oligo All received NSAID Eccocardiographic evaluation
of left ventricular function
Higher systolic and diastolic BP, but
within normal rate, and higher resting
heart rate in patients.
with an age matched
healthy control group
35 * poly Diastolic dysfunction and higher
systolic and diastolic dimensions and
volumes.sJIA
No numbers given
Pietrewicz et al.
2007 [83]
Descriptive cross-sectional 40 4–16 32 oligo No information Echocardiographic
assessment of cIMT
Increased cIMT in patients with JIA,
highest in children with polyarthritis,
and correlation between homocystein
and cIMTHomocysteine
with an age matched control
group of healthy children
23 * 3–17 * 8 poly CRP
Lipid profile Correlation between disease duration
and cIMT
Disease duration
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Table 3 Investigations of structure and function of heart and / or arteries in children and adolescents with JIA with no clinical signs of cardiovascular dysfunction (Continued)
Ref. Design No. of patients
and controls
Age-group Numbers of patients
and subtypes
Number of patients in
treatment at time of
investigation
Study parameters Significant findings
Vlahos et al.
2011 [84]
Descriptive cross-sectional 30 7–18 15 oligo 3 NSAID Echocardiographic
assessment of cIMT
Reduced FMD in patients (as a group)
associated with ESR but without any
association to medication or clinical
disease activitywith a BMI, sex, and age
matched control group of
healthy children
33 * 8 poly 4 corticosteroid PWV
FMD
7 sJIA 15 MTX Arterial compliance Increased cIMT in sJIA compared to
controls or non-systemic JIA and
related to use of corticosteroids,
disease activity, BMI, blood pressure,
dyslipidaemia, and age
9 TNF-inhibitor Disease activity
BMI
BP
Glucose
Lipid profile No difference in PWV or arterial
compliance between groups
Smoking
Koca et al.
2012 [85]
Descriptive cross-sectional 50 5–16 22 oligo No information Echocardiographic
assessment of left
ventricle function
Impaired diastolic function in patients
13 poly Electrographic
assessment
No arrhythmias
6 ERA
4 PsA
5 sJIAwith a sex, and age matched
control group of healthy
children
70 *
Follow-up after 12 month.
Abul et al.
2012 [86]
Descriptive cross-sectional 55 12.57 SD 2.9 24 oligo 22 NSAID Echocardiographic
assessment of right
ventricular function
Systolic and diastolic dysfunction of
the right ventricle
8 poly 31 Salazopyrin
15 ERA 31 MTX
with a BMI, sex, and age
matched control group of
healthy children
33 * 11.9 SD 2.7 * 1 PsA 25 Corticosteroid Disease activity No association to medication including
steroids and no associations to disease
activity7 sJIA 2 TNF-inhibitor
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Table 3 Investigations of structure and function of heart and / or arteries in children and adolescents with JIA with no clinical signs of cardiovascular dysfunction (Continued)
Ref. Design No. of patients
and controls
Age-group Numbers of patients
and subtypes
Number of patients in
treatment at time of
investigation
Study parameters Significant findings
Alkady et al.
2012 [66]
Descriptive cross- sectional 45 5–16 5 oligo NSAID Echocardiographic
assessment of systolic
and diastolic function
(36 patients)
Higher resting heart rate and higher
systolic and diastolic BP in patients but
within normal range. Also enlarged left
ventricular systolic dimensions and
diastolic dysfunction. In 6 patients was
found thickened pericardium, and in 9
mitral valve thickening and mild
dysfunction.No association with
disease activity reported.
10 poly 26 MTX
20 ERA 8 Corticosteroid
with a sex and age matched
control group of healthy
children
30 * 1 PsA Spirometry and CO
diffusion (30 patients)
9 sJIA
23 patients and controls
had both investigations
Disease activity and duration In 19 out of 30 patients was found a
reduction in pulmonary function
primarily of a restrictive pattern,
inversely correlated to disease duration
and severity / treatment with MTX
Breda et al.
2012 and
2013 [33, 34]
Longitudinal intervention
study of 12 months
38 4.7–9.4 Oligo- or poly NSAID cIMT Improvement in all baseline disease
parameters, including BT, after one year of
“ treatment to target” except cHDL that
was found normal at baseline and did not
change. Positive correlation between cIMT
and LDL and IL-1beta, no correlation to
CRP or ESR.BT was found elevated at
baseline but within normal range
Mild disease in 22 MTX at baseline. Clinical disease activity
ESR, CRP
with a sex, age and puberty
stage matched control group
of healthy children
40 * 4.1- 8.6* Aggressive disease
in 16 with poly
During follow-up disease
control was obtained by
22 in treatment with
NSAID +/- conventional
DMARDs
Proinflammatory cytokines
BP
Lipid profile
Oxidant status
16 patients needed more
aggressive treatment with
TNF-alfa inhibition
Glowinska-
Olszewska
et al. 2013 [32]
Descriptive cross- sectional 58 11–15 28 oligo 42 Corticosteroid BMI 22% of the patients met the criteria for
overweight or obesity.
26 poly 28 MTX FMD
4 sJIA 14 Biologics cIMT
Clin. active
inflammation: 30
9 Unspec. DMARDS LVMi Lower FMD and higher cIMT, LVMi, BMI,
and BP in patients as a group compared
to controls; highest cIMT and lowest
FMD in obese patients. No difference
between patients with clinically active
and inactive disease and no difference
between JIA subtypes.
Disease activity
BP
CRP
IL-6, TNF-alfa
Lipid profile
Insulin sensitivitywith a sex and age
matched control group
of healthy children with
normal weight; no obese
children
36 * 12-15 * Clin. inactive
inflammation: 28
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Table 3 Investigations of structure and function of heart and / or arteries in children and adolescents with JIA with no clinical signs of cardiovascular dysfunction (Continued)
Ref. Design No. of patients
and controls
Age-group Numbers of patients
and subtypes
Number of patients in
treatment at time of
investigation
Study parameters Significant findings
Raab et al.
2013 [36]
Descriptive cross- sectional
study of young adults with
severe JIA, based on
self-reports
344 19.7 SD 2.8 28 oligo 215 Biologics Comorbidity In 9.9% were reported CVD with
hypertension in 7.3%, not different from
the control group50 extended oligo
91 RFneg poly
37 RFpos poly 151 MTX Disease activity
75 ERA 64 Other conventional Health CVD, mainly hypertension, was
reported in 40.6% of 15 patients with
sJIA37 PsA DMARDs Functional deficits,
15 sJIA
11 other arthritisand compared to an age
and sex matched cohort
sampled from the general
population
688 *
Aulie et al.
2014 [37]
Cross-sectional, observational
study of patients with
disease duration of more
than 23 years
87 34.8–40.6 15 oligo 25 TNF-inhibitor BP Higher systolic and diastolic BT and
small elevation of PWV in patients
related to diastolic BT14 extended oligo 19 Methotrexate PWV
13 RF neg poly 23 Daily NSAID AIx
5 RF pos poly 6 Prednisolone Coronary calcification
18 ERA Disease activity No difference in AIx between patients
and controls, but a positive association
to diastolic BP, accumulated disease
parameters inclusive treatment with
prednisolone, and daily smoking, and a
negative association to vigorous physical
activity
15 PsA CRP, ESR
BMI and waist circumference
4 sJIA Lipid profile
3 unclassified Insulin resistance
Self reported habits of
smoking and physical
activity
With an age and sex matched
group without DM or
inflammatory arthritis selected
from a national population
register
87 * Coronary calcification was present in
26% of patients, a frequency not
different from that found in a large
population study, and related to waist
circumference, BMI, systolic BP, blood
glucose and years on daily prednisolone
Lianza et al.
2014 [77]
Two year prospective
observational study
21 2.2–17.8 21 poly TNF-inhibitor Systolic and diastolic cardiac
function evaluated by
echocardiography
Mild ventricular diastolic dysfunction in
JIA with no relation to NT-pro-BNP.
Possible association between NT-pro-
BNP and disease activity.
with age and sex matched
healthy controls
22 * 6 - 17 * Cardiac biomarkers:
NT-pro-BNP
Troponin T No sign of cardiovascular deterioration
during treatment with TNF-alfa inhibitor.
Disease activity
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Table 3 Investigations of structure and function of heart and / or arteries in children and adolescents with JIA with no clinical signs of cardiovascular dysfunction (Continued)
Ref. Design No. of patients
and controls
Age-group Numbers of patients
and subtypes
Number of patients in
treatment at time of
investigation
Study parameters Significant findings
Satija et al.
2014 [71]
Cross sectional,
observational
31 3.5–16 2 oligo No DMARD or biologics cIMT, Reduced arterial elasticity in patients
indicative of increased stiffness, all had
normal BT. No difference in cIMT, FMD,
GTN-MD between subgroups and
controls
2 RF neg poly Arterial elasticityFMD31 *
GTN-MD
BT
4 RF pos poly Disease activity
9 ERA ESR
14 sJIA Lipid-profile Correlation between cIMT and ESRWith an age and sex
matched control group
of healthy children
SD is given in brackets. Aix Augmentation index, aIMT aorta intima-media thickness, BP blood pressure, CAC, coronary artery calcification, cIMT, carotis intima-media thickness, ERA Entesitis-related arthritis, ESR
erythrocyte sedimentation rate, FMD flow mediated dilatation, GTN-MD glyceryl trinitrate mediated dilatation, LVMi left ventricle mass index, MTX Methotrexate, NSAID Non Steroid Anti-Inflammatory Drug, Oligo
oligoarticular JIA, RF Rheuma-factor, Poly Polyarticular JIA, PsA Psoriasis associated JIA, sJIA systemic JIA, DMARD disease modifying anti-rheumatic drugs, PWV pulse wave velocity
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Risk factors for premature subclinical atherosclerosis in
JIA
The studies included in this review use various tech-
niques for the assessment of cardiovascular function
and, except for the studies of young adults with JIA, in-
clude relatively small groups of children or adolescents
with variable subtypes of JIA in diverse states of activity
and on different medications. These different circum-
stances make meta- and subgroup-analyses difficult.
Nevertheless, taken together we find it reasonable to
conclude that surrogate markers of early atherosclerosis
are present more often in JIA patients than in their
healthy peers. Several studies, including those of young
adults with JIA, show a significantly higher rate of ele-
vated blood pressure, ventricular dysfunction and in-
creased cIMT as a general feature of JIA, possibly
associated with more pronounced systemic inflammation
and dyslipidemia. Also the signs of aortitis and myocar-
ditis, seen most prominently in patients with ERA
(Enthesitis-related arthritis), support the concept of per-
sistent systemic inflammation as an important driver of
premature cardiovascular disease.
Longer term follow-up studies, however, have not
shown any increase in clinically overt atherosclerotic
events in young adult (less than 41 years of age) with
long-standing JIA, which points to a slowly-developing,
multifaceted process which may be amenable to prevent-
ive measures.
Elevated blood pressure, prehypertension as seen in
several of the studies, is associated with increased cIMT
and Left Ventricle Mass Index (LVMi), diastolic dysfunc-
tion and arterial stiffness, independently of BMI but as-
sociated with dyslipidemia [38, 39]. Dyslipidemia may be
a feature of persistent inflammation [40–42] and may be
associated with Metabolic Syndrome (MetS), a cluster of
independent risk factors for atherosclerosis [43] that are
also associated with persistent inflammation [44]. The
occurrence of MetS in JIA has not yet been studied in
great detail (for a recent review see Zanette et al. [45]).
Glucocorticoid treatment may lead to insulin resistance
[46–49], which is a hallmark of MetS. Since the intro-
duction of MTX and specific biological inhibitors of in-
flammation, glucocorticoids are typically used in lower
dosages and for shorter periods of time, but may still be
a concern regarding metabolic dysfunction, risk of
hypertension and premature atherosclerosis as seen in
the studies by Raab et al. [36] and Aulie et al. [37]. In
European studies from 1969 and 1977, secondary amyl-
oidosis, with risk of hypertension due to kidney depos-
ition, was reported to occur in 5–7 % of JIA patients,
most often in children with systemic JIA. In a retro-
spective hospital-based study in Turkey [50] looking at
196 children with JIA from 1995 to 2004, only three pa-
tients (1.4 %) developed amyloidosis a frequency
comparable to that reported by Raab et al. [36]. Interest-
ingly, information on secondary amyloidosis in children
with JIA has only appeared in scattered case reports in
the last few years; presumably the prevalence of
secondary amyloidosis is declining, as more efficient
anti-inflammatory medications have become available.
By addressing chronic inflammation aggressively, the
impact of the known risk factors for premature develop-
ment of atherosclerosis (i.e. hypertension, dyslipidemia,
and insulin resistance), may well diminish in parallel
with the decreasing inflammation; preventable risk fac-
tors (including overweight, physical inactivity, and to-
bacco smoking) should then be considered.
High BMI (overweight and obesity) is by itself, associ-
ated with low grade systemic inflammation [51–55]. As
elevated BMI could, thus, potentially amplify a preexist-
ing inflammatory condition and thereby enhance the risk
of premature atherosclerosis, a number of studies have
looked at overweight and obesity in patients with JIA. In
a recent cross-sectional study of 154 American children
and adolescents with JIA, 18 % met criteria for obesity
and an additional 12 % were overweight, similarly to
what is seen in otherwise healthy American children
[56]. The authors did not find an association between
obesity and clinical disease activity, duration of illness or
medication; markers of inflammation (CRP and ESR) did
not correlate with BMI. Statistical power was, however,
limited in this relatively small study which did not in-
clude healthy controls. Two other small recent cross-
sectional studies of children and adolescents with JIA, in
Morocco [57] and Poland [32], found higher rates of
obesity and overweight than reported in the national ref-
erences. In the study from Poland obese patients had
higher levels of inflammatory markers in the blood, dys-
lipidemia and signs of insulin resistance as well as higher
blood pressure compared to normal weight patients, but
there were no obese healthy children in the control
group. A controlled cross-sectional study from Brazil,
looking at body composition in 42 female children and
adolescents with JIA, showed increased body fat and
truncal fat in prepubertal children with JIA, independent
of subtype and medication [58]; this finding is of interest
since abdominal fat is considered the origin of systemic
inflammation associated with obesity. Weight gain and
increase in visceral fat have been described in patients
with RA receiving TNF-α- and IL-6-inhibitors, but
weight gain was not found in a cohort of children with
JIA on TNF-α inhibitor therapy compared with JIA pa-
tients not treated with TNF-α inhibitors [59]; body com-
position was, however, not assessed.
Physical inactivity is another modifiable risk factor for
premature atherosclerosis [16–21]. More specifically, a
study on adolescents and young adults by Edwards et al.
[18] showed that higher PA was an independent
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predictor for lower arterial stiffness, measured as periph-
eral arterial distensibility and AIx.
In children with JIA, a sedentary lifestyle due to pain,
fatigue and sleep disturbances is not uncommon [60].
Lelieveld et al. [61] found low fitness and low levels of
PA in adolescents with JIA compared to healthy chil-
dren. The inactive lifestyle was, however, unrelated to
the degree of disease activity, and remission of clinical
symptoms did not result in a more active lifestyle, which
signifies complex reasons for physical inactivity in these
patients. Also a recent study [62] reported reduced PA
unrelated to pain or objective signs of inflammation in
children and adolescents with JIA. Unfortunately PA was
only assessed in one of the investigations on subclinical
atherosclerosis in JIA [37] and in that study only by self-
reports, a less reliable means of assessment.
A cross-sectional study of fitness in children with JIA
showed significantly lower aerobic capacity among chil-
dren aged 6 to 11 years with polyarticular JIA compared
with matched healthy controls [63]. This finding was
supported by a subsequent meta-analysis of 5 studies
with a total of 144 children [64] and a more recent study
[65], in which the investigators found a significant nega-
tive correlation between disease activity and aerobic cap-
acity in children, adolescents and young adults across all
JIA subtypes. Also patients in remission were found to
have reduced aerobic capacity. Details regarding PA are
not given, but the authors state that the lower aerobic
capacity was not simply explained by sedentary lifestyle,
and the authors speculate that muscle wasting, lung dys-
function, as also found by Alkady et al. [66], and anemia
due to chronic inflammation may be important contrib-
uting factors. In healthy children, Dencker et al. [67] also
found only a weak association between PA and aerobic
fitness. This could be due to assessment methods, as
intervention studies show increased aerobic fitness con-
nected with increased PA [17]. Muscle wasting, lung
dysfunction, and anemia due to chronic inflammation
should diminish in the wake of more effective disease
control, thus making regular PA possible for patients
with JIA.
Finally, tobacco smoking is still a common and im-
portant risk factor for development of cardiovascular
disease in teenagers and young adults [68]. In a ques-
tionnaire study of US adolescents with JIA, as many
as 15.4 % reported use of tobacco in the last year
[69]. A cross-sectional survey from Switzerland, of
7253 adolescents aged 16 to 20 years, adolescents
with a chronic condition, defined as a disability or a
disease lasting > 6 months and requiring continuous
medical care, reported significantly higher rates of
risk behavior including tobacco smoking than in a
comparison group of healthy adolescents [70]. The in-
vestigation by Aulie et al. [37] likewise reported a
significantly higher rate of daily smoking in the pa-
tients than in controls.
Conclusions
In this review of the current literature we find convin-
cing evidence for the existence of subclinical signs of
premature atherosclerosis in patients with JIA, but the
studies available do not provide a clear picture as to the
cause. Inflammation is probably a driver, but attention
must also be paid to other known risk factors for devel-
opment of atherosclerosis, including obesity, physical in-
activity and tobacco smoking - risk factors which are
open to modification by changes in lifestyle.
With the advent of increasingly effective drugs for
treating chronic inflammatory diseases in childhood and
adolescence, and the resulting reduced risk of concomi-
tant functional impairment, we should now broaden our
strategy of management and address other potential
consequences of chronic disease.
Reestablishment of a healthy lifestyle, including avoid-
ance of adipositas and physical inactivity, is of great im-
portance for gaining the full benefit of effective anti-
inflammatory treatment and in securing a healthy life in
adulthood.
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